Analyst David Risinger upgraded shares to outperform. He also raised his price target to $834 from $762.
Leerink upgrades this beaten-down biotech stock, says investors should buy the dip
Categories:
Related Post
Trial of man accused in Trump assassination attempt in Florida pushed backTrial of man accused in Trump assassination attempt in Florida pushed back
Ryan Wesley Routh is being held in Miami awaiting trial in Fort Pierce.
Avoiding Siri slipups and apologies for butt dialsAvoiding Siri slipups and apologies for butt dials
When it comes to using voice assistants across multiple devices, things can get a bit tricky. “Mike” from St. George, Utah, found himself in a comical yet frustrating situation with